查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
無細胞 DNA 分離和萃取市場 - 全球及區域分析：按產品、平台、技術、應用、最終用戶和區域 - 分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1703926

無細胞 DNA 分離和萃取市場 - 全球及區域分析：按產品、平台、技術、應用、最終用戶和區域 - 分析和預測（2025-2035 年）

Cell-Free DNA Isolation and Extraction Market - A Global and Regional Analysis: Focus on Product, Platform, Techniques, Application, End User, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 130 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

由於癌症發病率不斷上升、主要參與企業的舉措不斷增多以及政府在無細胞 DNA 分離和提取市場中不斷加大的舉措，無細胞 DNA 分離和提取試劑套件、試管和其他消耗品的使用量正在增加。

醫療保健公司持續大力投資以滿足行業需求，以及主要終端用戶擴大採用無細胞 DNA 分離和提取套件、試管和試劑是推動全球無細胞 DNA 分離和提取市場成長的主要因素。

全球無細胞 DNA 分離和萃取市場由老字型大小企業公司和新興企業組成。一些公司正試圖透過推出從不同樣本類型中分離和提取無細胞 DNA 的新產品並為新產品開發籌集資金來保持其在市場上的地位。 2021 年 1 月至 2025 年 3 月期間，全球無細胞 DNA 分離和提取市場的主要市場參與企業已經看到了產品發布、產品核准、商業資金籌措和協同活動。該公司推出產品的傾向表明公司正在不斷將新產品推向市場以分離無細胞 DNA，這主要是由於液態切片研究的增加和監管機構核准了幾種液態切片檢測。

本報告探討的關鍵問題

  • 無細胞 DNA 分離和萃取如何徹底改變腫瘤學？
  • 全球無細胞 DNA 分離和提取市場的主要促進因素、挑戰和機會是什麼？
  • 全球無細胞 DNA 分離和提取市場新興趨勢的底層結構是什麼？
  • 為了在競爭激烈的市場中生存，主要企業正在實施哪些關鍵發展策略？
  • 已開發地區和發展中地區在使用無細胞 DNA 分離和提取進行標靶治療的主要監管影響是什麼？
  • 進入特定地區的公司預計會面臨哪些潛在的進入障礙？
  • 預測期內（2025-2035 年），每個細分市場預計如何成長，預計每個細分市場將產生多少收益？以下是片段：
    • 產品（遊離DNA萃取分離試劑套件、萃取分離管、其他耗材）
    • 平台（聚合酵素鏈鎖反應（PCR）、次世代定序（NGS）、其他平台）
    • 技術（以微珠為基礎、基於旋轉管柱、其他技術）
    • 應用（非侵入性產前檢測 (NIPT)、腫瘤學、移植排斥和其他應用）
    • 最終用戶（製藥和生物技術公司、學術和研究機構、CRO 和其他最終用戶）
    • 地區（北美、歐洲、亞太地區、拉丁美洲、世界其他地區）
  • 企業發展地區的無細胞DNA分離和萃取公司有哪些成長機會？
  • 全球無細胞 DNA 分離和萃取市場中提供關鍵產品的主要企業有哪些？
  • 還有，這是為什麼呢？

本報告概述了全球無細胞 DNA 分離和萃取市場，包括產品、平台、技術、應用、最終用戶和地區的趨勢，以及參與市場的公司概況。

目錄

執行摘要

第1章 市場概述

  • 市場定義
  • cfDNA的早期檢測與應用
  • cfDNA的特徵
  • cfDNA的生物學作用
  • 循環cfDNA的提取
  • 循環cfDNA的應用
  • 市場足跡和成長潛力
  • 研究、臨床開發和商業活動的中斷

第2章全球無細胞 DNA 分離與萃取市場：產業分析

  • 概述
  • 美國法律要求與框架
    • FDA法規
  • 亞太地區的法律要求與框架
    • 中國
    • 日本

第3章 市場動態

  • 概述
  • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第4章 競爭格局

  • 概述
  • 產品發布和升級
  • 產品核可和商業融資
  • 協同效應活動
  • 合併與收購
  • 2023 年及 2024 年市場佔有率分析（按公司）
  • 成長佔有率分析（按公司）

5. 全球無細胞DNA分離和提取市場（按產品）百萬美元，2023-2035年

  • 概述
  • 無細胞DNA分離萃取試劑套件
  • 無細胞DNA分離萃取管
  • 其他耗材

6. 全球無細胞DNA分離與萃取市場（按平台分類），百萬美元，2023-2035年

  • 概述
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 即時聚合酵素鏈鎖反應（RT-PCR）
  • 數位聚合酵素鏈鎖反應（dPCR）
  • 其他

7. 全球無細胞 DNA 分離與萃取市場（按技術分類），百萬美元，2023-2035 年

  • 概述
  • 以微珠為基礎
  • 基於旋轉管柱
  • 其他

8. 全球無細胞DNA分離與萃取市場（按應用），百萬美元，2023-2035年

  • 概述
  • 非侵入性產前檢測（NIPT）
  • 腫瘤學
    • 固態腫瘤
    • 造血系統惡性腫瘤
  • 移植排斥
  • 其他

9. 全球無細胞DNA分離和提取市場（按最終用戶分類），百萬美元，2023-2035年

  • 概述
  • 製藥和生物技術公司
  • 學術研究機構與研究中心
  • CRO
  • 臨床診斷中心
  • 其他

第 10 章。全球無細胞 DNA 分離和萃取市場（按地區分類，百萬美元，2023 年至 2035 年）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 丹麥
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 新加坡
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 其他地區

第11章 公司簡介

  • Thermo Fisher Scientific Inc.
  • QIAGEN
  • Danaher Corporation
  • PerkinElmer, Inc.
  • Endress+Hauser AG
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • llumina, Inc.
  • Takara Bio Inc.
  • Aline Biosciences
  • EpiGentek Group, Inc.
  • Omega Bio-tek, Inc.
  • Promega Corporation
  • Streck, Inc.
  • AccuBioMed Co., Ltd.
  • AMSBIO
  • Covaris, Inc.
  • EntroGen, Inc.
  • NeoGeneStar LLC
  • Norgen Biotek Corporation
  • STRATEC SE
  • System Biosciences, LLC

第12章調查方法

簡介目錄
Product Code: BHP0590SC

Introduction to Cell-free DNA Isolation and Extraction Market

The use of cell-free DNA isolation and extraction kits, tubes, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives in the cell-free DNA isolation and extraction market. The constant significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and reagents among major end users are the major factors propelling the growth of the global cell-free DNA isolation and extraction market.

Competitive Landscape

The global cell-free DNA isolation and extraction market comprise well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the isolation and extraction of cell-free DNA from different sample types. Key market players of the global cell-free DNA isolation and extraction market witnessed product launch, product approval and business funding, and synergistic activities majorly during the period January 2021-March 2025. The inclination of companies toward product launches suggests that the companies are involved in continuously bringing new products to the market to isolate cell-free DNA, which is primarily attributed to an increase in liquid biopsy studies and approval of several liquid biopsy assays by the regulatory agencies.

Market Segmentation:

Market Segmentation:

Segmentation 1: by Product

  • Cell-Free DNA Extraction and Isolation Kits
  • Extraction and Isolation Tubes
  • Other Consumables

Segmentation 2: by Platforms

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Other

Segmentation 3: by Technique

  • Magnetic Beads-Based
  • Spin Column-Based
  • Other

Segmentation 4: by Application

  • Non-Invasive Prenatal Testing (NIPT)
  • Oncology
  • Transplant Rejection
  • Other Applications

Segmentation 5: by End User

  • Academic Research Institutes and Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Clinical Diagnostic Centers
  • Contract Research Organizations (CROs)
  • Others (Forensic, Biobanks)

Segmentation 6: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World

Key Questions Answered in the Report

  • How is cell-free DNA isolation and extraction revolutionizing oncology?
  • What are the major market drivers, challenges, and opportunities in the global cell-free DNA isolation and extraction market?
  • What are the underlying structures resulting in the emerging trends within the global cell-free DNA isolation and extraction market?
  • What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of cell-free DNA isolation and extraction-targeted therapies?
  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
  • How is each market segment expected to grow during the forecast period 2025-2035, and what is the anticipated revenue to be generated by each segment? Following are the segments:
    • Product (Cell-Free DNA Extraction and Isolation Kits, Extraction and Isolation Tubes, Other Consumables)
    • Platform (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Other Platforms)
    • Technique (Magnetic Beads-Based, Spin Column-Based, and Other Techniques)
    • Application (Non-Invasive Prenatal Testing (NIPT), Oncology, Transplant Rejections, Other Applications)
    • End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), and Other End Users)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the cell-free DNA isolation and extraction companies in the region of their operation?
  • Who are the leading players with significant offerings in the global cell-free DNA isolation and extraction market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets Overview

  • 1.1 Market Definition
  • 1.2 Early Discovery and Application of cfDNA
  • 1.3 Properties of cfDNA
  • 1.4 Biological Role of cfDNA
  • 1.5 Extraction of Circulating cfDNA
  • 1.6 Application of Circulating cfDNA
  • 1.7 Market Footprint and Growth Potential
  • 1.8 Interruption in Research and Clinical Development and Commercial Operation
    • 1.8.1 Research and Clinical Development
    • 1.8.2 Commercial Operation
    • 1.8.3 Navigating Crisis Recovery and Looking to the Future

2. Global Cell-Free DNA Isolation and Extraction Market: Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S.
    • 2.2.1 FDA Regulation
  • 2.4 Legal Requirements and Framework in Asia-Pacific
    • 2.4.1 China
    • 2.4.2 Japan

3. Market Dynamics

  • 3.1 Overview
  • 3.2 Impact Analysis
  • 3.3 Market Drivers
  • 3.4 Market Restraints
  • 3.5 Market Opportunities

4. Competitive Landscape

  • 4.1 Overview
  • 4.2 Product Launch and Upgradations
  • 4.3 Product Approvals and Business Funding
  • 4.4 Synergistic Activities
  • 4.5 Mergers and Acquisitions
  • 4.6 Market Share Analysis (by Company), 2023 and 2024
  • 4.7 Growth Share Analysis (by Company)

5. Global Cell-Free DNA Isolation and Extraction Market (by Product) $Million, 2023-2035

  • 5.1 Overview
  • 5.2 Cell-Free DNA Isolation and Extraction Kits
  • 5.3 Cell-Free DNA Isolation and Extraction Tubes
  • 5.4 Other Consumables

6. Global Cell-Free DNA Isolation and Extraction Market (by Platform), $Million, 2023-2035

  • 6.1 Overview
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 Real-Time Polymerase Chain Reaction (RT-PCR)
  • 6.5 Digital Polymerase Chain Reaction (dPCR)
  • 6.6 Other Platforms

7. Global Cell-Free DNA Isolation and Extraction Market (by Techniques), $Million, 2023-2035

  • 7.1 Overview
  • 7.2 Magnetic Beads-Based
  • 7.3 Spin Column-Based
  • 7.4 Other Techniques

8. Global Cell-Free DNA Isolation and Extraction Market (by Application), $Million, 2023-2035

  • 8.1 Overview
  • 8.2 Non-Invasive Prenatal Testing (NIPT)
  • 8.3 Oncology
    • 8.3.1 Solid Tumor
    • 8.3.2 Hematological Malignancies
  • 8.4 Transplant Rejection
  • 8.5 Other Applications

9. Global Cell-Free DNA Isolation and Extraction Market (by End User), $ Million, 2023-2035

  • 9.1 Overview
  • 9.2 Pharmaceutical and Biotechnology Companies
  • 9.3 Academic Research Institutes and Laboratories
  • 9.4 Contract Research Organizations (CROs)
  • 9.5 Clinical Diagnostic Centers
  • 9.6 Other End Users

10. Global Cell-Free DNA Isolation and Extraction Market (by Region), $ Million, 2023-2035

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 U.K.
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Denmark
    • 10.3.7 Rest-of-Europe
  • 10.4 Asia-Pacific
    • 10.4.1 China
    • 10.4.2 India
    • 10.4.3 Japan
    • 10.4.4 South Korea
    • 10.4.5 Australia
    • 10.4.6 Singapore
    • 10.4.7 Rest-of-Asia-Pacific (RoAPAC)
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest-of-Latin America (RoLA)
  • 10.6 Rest-of-the-World

11. Company Profiles

  • 11.1 Thermo Fisher Scientific Inc.
    • 11.1.1 Company Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Target Customers/End Users
    • 11.1.4 Analyst View
  • 11.2 QIAGEN
    • 11.2.1 Company Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Target Customers/End Users
    • 11.2.4 Analyst View
  • 11.3 Danaher Corporation
    • 11.3.1 Company Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Target Customers/End Users
    • 11.3.4 Analyst View
  • 11.4 PerkinElmer, Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Target Customers/End Users
    • 11.4.4 Analyst View
  • 11.5 Endress+Hauser AG
    • 11.5.1 Company Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Target Customers/End Users
    • 11.5.4 Analyst View
  • 11.6 Agilent Technologies, Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Product Portfolio
    • 11.6.3 Target Customers/End Users
    • 11.6.4 Analyst View
  • 11.7 F. Hoffmann-La Roche Ltd.
    • 11.7.1 Company Overview
    • 11.7.2 Product Portfolio
    • 11.7.3 Target Customers/End Users
    • 11.7.4 Analyst View
  • 11.8 Merck KGaA
    • 11.8.1 Company Overview
    • 11.8.2 Product Portfolio
    • 11.8.3 Target Customers/End Users
    • 11.8.4 Analyst View
  • 11.9 llumina, Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Product Portfolio
    • 11.9.3 Target Customers/End Users
    • 11.9.4 Analyst View
  • 11.10 Takara Bio Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Product Portfolio
    • 11.10.3 Target Customers/End Users
    • 11.10.4 Analyst View
  • 11.11 Aline Biosciences
    • 11.11.1 Company Overview
    • 11.11.2 Product Portfolio
    • 11.11.3 Target Customers/End Users
    • 11.11.4 Analyst View
  • 11.12 EpiGentek Group, Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Product Portfolio
    • 11.12.3 Target Customers/End Users
    • 11.12.4 Analyst View
  • 11.13 Omega Bio-tek, Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Product Portfolio
    • 11.13.3 Target Customers/End Users
    • 11.13.4 Analyst View
  • 11.14 Promega Corporation
    • 11.14.1 Company Overview
    • 11.14.2 Product Portfolio
    • 11.14.3 Target Customers/End Users
    • 11.14.4 Analyst View
  • 11.15 Streck, Inc.
    • 11.15.1 Company Overview
    • 11.15.2 Product Portfolio
    • 11.15.3 Target Customers/End Users
    • 11.15.4 Analyst View
  • 11.16 AccuBioMed Co., Ltd.
    • 11.16.1 Company Overview
    • 11.16.2 Product Portfolio
    • 11.16.3 Target Customers/End Users
    • 11.16.4 Analyst View
  • 11.17 AMSBIO
    • 11.17.1 Company Overview
    • 11.17.2 Product Portfolio
    • 11.17.3 Target Customers/End Users
    • 11.17.4 Analyst View
  • 11.18 Covaris, Inc.
    • 11.18.1 Company Overview
    • 11.18.2 Product Portfolio
    • 11.18.3 Target Customers/End Users
    • 11.18.4 Analyst View
  • 11.19 EntroGen, Inc.
    • 11.19.1 Company Overview
    • 11.19.2 Product Portfolio
    • 11.19.3 Target Customers/End Users
    • 11.19.4 Analyst View
  • 11.20 NeoGeneStar LLC
    • 11.20.1 Company Overview
    • 11.20.2 Product Portfolio
    • 11.20.3 Target Customers/End Users
    • 11.20.4 Analyst View
  • 11.21 Norgen Biotek Corporation
    • 11.21.1 Company Overview
    • 11.21.2 Product Portfolio
    • 11.21.3 Target Customers/End Users
    • 11.21.4 Analyst View
  • 11.22 STRATEC SE
    • 11.22.1 Company Overview
    • 11.22.2 Product Portfolio
    • 11.22.3 Target Customers/End Users
    • 11.22.4 Analyst View
  • 11.23 System Biosciences, LLC
    • 11.23.1 Company Overview
    • 11.23.2 Product Portfolio
    • 11.23.3 Target Customers/End Users
    • 11.23.4 Analyst View

12. Research Methodology